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Summary It is well established that hepatitis C develops into cirrhosis of the liver and
hepatocellular carcinoma (HCC) both of which are fatal diseases. The World Health Organization
estimates that there are at least 21.3 million hepatitis C virus (HCV) carriers in the Eastern
Mediterranean countries, which is close to the number of carriers estimated in the Americas and
Europe combined. With such a high disease burden of HCV infection in this part of the world, and
in light of the new evidence that genotypes may influence the outcome of antiviral therapy, the
focus of this review is on the epidemiology and distribution of HCV genotypes in the Eastern
Mediterranean countries. Accumulated data show that there are two main patterns for the
distribution of HCV genotypes in the Middle East: in the first pattern, genotype 4 is prevalent in
most of the Arab countries, and in the second pattern, genotype 1a or 1b predominates in the non-
Arab countries. Results from the limited number of clinical trials on the treatment of chronic HCV
genotype 4 using peginterferon alfa-2b in combination with ribavirin are encouraging. However,
efforts to develop more effective antiviral therapies and the establishment of an effective HCV
vaccine remain the largest challenges for the near future.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
In 1999, theWorld Health Organization (WHO) estimated that
170 million individuals were chronically infected with the
hepatitis C virus (HCV) worldwide.1 Furthermore, it is now* Corresponding author. Tel.: +961 1 350000x4698;
fax: +961 1 744470.
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doi:10.1016/j.ijid.2005.07.008well established that hepatitis C develops into cirrhosis of the
liver and hepatocellular carcinoma (HCC) both of which are
fatal diseases.2—6 These facts clearly indicate that HCV is an
important public health problem globally.
To date, numerous data have been accumulated on the
epidemiology of HCV infection.7,8 Accumulated data show
that HCV genotypes vary in their distribution, which may
have clinical significance.9—11 The WHO estimates that there
are at least 21.3 million HCV carriers in the Eastern Medi-
terranean countries, which is close to the number of carriersPublished by Elsevier Ltd. All rights reserved.
Distribution of hepatitis C virus genotypes in the Middle East 273estimated in the Americas (13.1 million) and Europe (8.9
million) combined.1 Indeed, one of the highest prevalences
of HCV infection (18.1%) has been reported from Egypt, a
Middle Eastern country.1 With such a high disease burden of
HCV infection in this part of the world and in light of the new
evidence that genotypes may influence the outcome of
antiviral therapy,12—15 the focus of this review is on the
epidemiology of HCV infection and distribution of HCV geno-
types in the Eastern Mediterranean countries and possible
implications for the future. However, since there have been
dramatic advances in the diagnosis of HCV infection during
the past decade, this article first reviews the molecular
organization and the genetic diversity of the HCV genome,
and then highlights the significance and reliability of the tests
available for testing and confirmation of HCV genotypes.
HCV genome
Genomic organization
HCV is an aspheric, enveloped virus classified in the Hepa-
civirus genus of the Flaviviridai family.16 The viral genome is a
single stranded linear RNA of positive sense. The genome is
approximately 9.6 kb in size and contains an open reading
frame (ORF) flanked by both a 50 and a 30 non-coding region
(NC).17 Immediately downstream of the 50 NC is the single
ORF, which encodes a large protein polyprotein precursor.
This precursor is subsequently cleaved by host and viral
proteases into various structural and nonstructural proteins.
The structural proteins are at the 50 end and include the
capsid or core protein (c), two envelope proteins (E1 and E2)
and a small protein of unknown function (P7). The structural
proteins are followed by at least six nonstructural (NS)
proteins denoted as NS2, NS3, NS4A, NS4B, NS5A, and NS5B.10
Genetic diversity of the HCV genome
Although both the 50 and 30 NC of the HCV genome possess
highly conserved terminal sequences,18 HCV is characterized
by a high degree of genetic heterogeneity19 and as such it is
similar to other RNA viruses. The most heterogeneous regions
of the genome are the genes encoding the two envelope
proteins, E1 and E2. The N terminus of the E2 gene contains
the most variable region of the entire genome and has been
referred to as the first hypervariable region (HVR1).20 A second
hypervariable region, referred to as HVR2, is located just 30 of
HVR1.21 This genetic heterogeneity of HCV has been classified
into four hierarchical strata: genotypes, subgenotypes (sub-
types), isolates, and quasi-species. The degree of nucleotide
sequence variation for each stratum (expressed as a percen-
tage) is 30—50%, 15—30%, 5—15%, and 15%, respectively.12,22
A total of eleven major genotypes, designated according
to the order of their discovery1—11 have been identified23,24
and more than 90 subtypes have been described. An increas-
ing number of novel subtypes is emerging and more detailed
phylogenetic analysis of these isolates is recommended.25,26
Testing for HCV genotypes
Many methods have been used for HCV genotyping including
genomic amplification and sequencing,27 restriction frag-ment length polymorphism (RFLP) of the PCR amplifications28
and differential hybridization.29 Among these direct meth-
ods, genomic amplification and sequencing, followed by
sequence comparison and phylogenetic tree construction
for confirmation is considered the gold standard. The geno-
mic regions commonly used in this approach include core, E1,
NS5 and 50 NC.30
More recently, HCV genotyping has been determined
indirectly by testing for type-specific antibodies with a com-
petitive enzyme immunoassay.31 However, although com-
parative analysis has shown a good overall agreement
between serotyping and molecular genetic analysis32 the
sensitivity of PCR-based assays over serologic assays has been
distinctly higher.31,32
Epidemiology of HCV genotypes
Worldwide
The worldwide distribution of HCV genotypes and their sub-
types is shown in Table 1. Genotypes 1, 2, and 3 are the most
frequently encountered genotypes worldwide.33—35 However,
significant differences are noticed when subtype distribution
is investigated. In North America and Northern Europe, 1a is
the most common subtype followed by 2b and 3a.36,37 The
most common subtype in Southern and Eastern Europe is 1b,
followed by genotypes 2 and 3.38,39 Although HCV subtypes 2a
and 2b are relatively common in North America and Europe,
subtype 2c is found commonly in Northern Italy.40 Subtype 3a,
which is endemic in South East Asia,34 has been encountered
in Europe and the USA, and with relatively high frequency in
intravenous drug abusers (IVDA).41,42 This leads to the sug-
gestion that this subtypemay have originated from South East
Asia and was introduced to Europe and North America by
travelers.43 In North Africa, similar to the situation in Eastern
and Southern Europe, HCV subtype 1b seems to predomi-
nate.44—46 In Tunisia, subtype 1b is largely the dominant
subtype (79%) followed by 1a, 2a, 2b, 3a, and 4.43 In Morocco
in contrast to Tunisia45,46 subtype 1b, although the most
prevalent, had lower prevalences (47—48%) but a higher
circulation of genotype 2 (29—37%).46 The pattern in Tunisia
is reminiscent of that in Japan where subtype 1b accounts for
73% followed by genotype 2 (20%) and subtype 1a (2%).34
Genotypes other than 1, 2 and 3 are actually more com-
mon among HCV-infected people in other parts of the world.
Genotype 4 seems to be confined to the Middle East47 and
Central Africa,48—50 while HCV genotype 5 has been isolated
almost exclusively in South Africa51 where it predominates,
followed by genotypes 1, 2, 3, and 4, respectively.51 Geno-
type 6 has been isolated in Hong Kong, Vietnam and through-
out South East Asia.52—54 In one study from Vietnam,
genotype 1 was the most common genotype followed by
genotypes 6—9 and genotype 2.55 HCV genotypes 7, 8, and
9 have been identifiedmainly in Vietnamese patients,56 while
genotypes 10 and 11 have been reported from Indonesia.57 It
has been suggested that genotypes 7—11 are variants of the
same group and should be classified as members of genotype
6.16 It is interesting to note that in the Philippines, HCV
subtype distribution is similar to that seen in North America
and Northern Europe, where subtype 1a is the most common
followed by 1b, 2a and 2b.58
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Table 1 Worldwide distribution of hepatitis C virus genotypes and subtypes
Region Genotype/subtype References
Most common Less common
North America 1a 1b, 2b, 3a 36,37
Europe
Northern Europe 1a 1b, 2, 3a 36,37
Southern and Eastern Europe 1b 1a, 2, 3, 2c 38,39
Japan 1b 2a, 2b, 3b 34
Africa
North Africa *
Tunisia 1b 1a, 2a, 2b, 3a, 4 44
Morocco 1b 2a, 2c, 1a 45,46
Central Africa
Gabon 4 1a, 1b, 2a, 2b 48
Nigeria 1, 4 2 49
Cameroon 4 1, 2 50
South Africa 5 1, 2, 3 and 4 51
South East Asia
Throughout the region 1 6, 7, 8, 9, 2 52—55
Vietnam, Thailand and Myanmar 7, 8, 9 10, 11 56
Indonesia 10, 11 1a 57
Philippines 1a 1b, 2a, 2b 58
* Excluding Egypt.Middle East
Distribution of HCV genotypes and subtypes in the Middle
East59—76 is shown in Table 2. Surprisingly, the accumulated
data show that there are two main patterns for the distribu-
tion of HCV genotypes: one is peculiar to the Arab countries
(except for Jordan) where genotype 4 predominates, whileTable 2 Distribution of hepatitis C virus genotypes and
subtypes in the Middle East
Region Genotype/subtype References
Most
common
Less
common
Arab countries
Egypt 4 1a, 1b, 2a 59—61
Gaza Strip 4 1, 3a 62
Jordan 1a 1b, 4 63
Kuwait 4 1 64
Lebanon 4 1a, 1b 65,66
Saudi Arabia 4 1a, 1b, 3a 67—70
Syria 4 1b,1a 71
Non-Arab countries
Iran
South 1a 1b 72,73
North West 3a 4
Israel 1b 1a, 2 62,74
Turkey 1b 1a 75,76the other pattern is characteristic of the non-Arab countries
(Turkey, Israel, and Iran) where genotype 1 predominates.
Although varying prevalences of genotype 4 have been
reported from the Arab countries, it is noteworthy that
genotype 4 is quasi-exclusive (91%) in Egypt which is also a
North African country.59—61 Based on only one known study in
Jordan, 1a is the dominant subtype (40%) followed by 1b
(33.3%) and genotype 4 (26.6%).63
In Turkey75,76 and in Israel62,74 subtype 1b is the dominant
subtype (>70%) followed by 1a, similar to the pattern seen in
Eastern and Southern Europe.38,39 Subtype 1a is the most
common subtype in Iran followed by 3a, 1b, and 4.72,73
The two different patterns for the distribution of HCV
genotypes in the Middle East are evident in the study con-
ducted to determine genotypes of HCV in the Gaza Strip and
Southern Israel.62 The Gaza Strip borders the southern part of
Israel and Egypt, and a few thousand inhabitants cross the
border daily from Gaza to both countries. The most common
genotypes found were type 1b (62%) in Southern Israel and
type 4 (78%) in the Gaza Strip, corresponding to the most
prevalent genotype in Egypt.61 The high similarity between
type 4 isolates from Gaza Strip and Egypt was demonstrated
by sequence analysis of the HCV 50 NC region.62 Subtype 1b in
Israel was followed by subtypes 1a, 2a/2c, and 3a, respec-
tively, and no genotype 4 was found.62
Although genotype 4 is generally uncommon in Western
countries, varying prevalences have been reported in South-
ern Europe.77—79 During the past two years it has become
evident that the number of patients infected with HCV
genotype 4 in Europe80,81 and the USA,82 and most recently
in Southern India,83 is rising. This emerging pattern might
reflect changing immigration patterns in those areas.
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Clinical significance of HCV genotypes
The significance of HCV genotyping as an epidemiological
marker has been clearly substantiated, particularly in tracing
the sources of infection and elucidating the possible modes of
transmission.84,85 However, the issue of pathogenicity of the
different genotypes/subtypes is still controversial.9—11,16
Several environmental, genetic, and immunological factors
may contribute to the profound differences in disease pro-
gression observed in HCV infected patients. Therefore, long-
term prospective studies in various population groups are still
needed to generate reliable data on the clinical significance
of HCV genotypes.
Antiviral therapy
In addition to the importance of HCV genotyping as epide-
miological markers, most investigators agree on the signifi-
cance of HCV genotypes as independent predictors of
response to antiviral therapy. Major clinical trials of antiviral
therapy for chronic HCV have been performed in Western
countries84,85 and in Japan.86 Hence, existing published data
largely deal with patients with HCV genotypes 1, 2, and 3,
and there are now clear-cut guidelines for the type of
treatment and duration of antiviral therapy in such
patients.87 However there have been relatively few studies
that have targeted patients infected with HCV genotype 4,
and combination therapy clinical trials (interferon and riba-
virin) for these patients have not been promising.88—90
Encouraging results are now being reported on the efficacy
of peginterferon in combination with ribavirin given for 48
weeks for the treatment of chronic hepatitis caused by HCV
genotype 491—97 with a sustained virologic response ranging
from 63 to 82%.91—94 It is evident that more randomized
controlled trials of the combined peginterferon plus ribavirin
are needed to assess the optimal dosage and duration of
therapy and for the eventual establishment of appropriate
treatment protocols for these patients.
Challenges
It is now clear that HCV genotype 4 is the predominant
genotype in the Middle East where one-fifth of the estimated
170 million HCV carriers live. In addition to the possible
development of the infection into cirrhosis and HCC, it has
been recently observed that there is an increased risk of liver-
related death and demand for liver transplantation in patients
infected with HCV genotype 4.98 These facts indicate that the
treatment of carriers and prevention of HCV infection are very
urgent problems. Efforts to develop more effective antiviral
therapies and the establishment of an effective HCV vaccine
remain the largest challenges for the near future.
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